Actively Recruiting
Phenotypic and Transcriptomic Description of Megakaryocytes in Sickle Cell Patient
Led by University Hospital, Toulouse · Updated on 2025-03-20
40
Participants Needed
1
Research Sites
159 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Sickle cell disease is the most common inherited blood disorder in the world. Chronic hemolysis induces platelet activation and chronic inflammation. Platelets and megakaryocyte, as medullar platelets precursors, are known to play a role in innate immunity. Little is known about the role of megakaryocytes at basal state and during acute complication in sickle cell disease patients. The aim of this study is to evaluate the role of megakaryocytes in sickle cell disease.
CONDITIONS
Official Title
Phenotypic and Transcriptomic Description of Megakaryocytes in Sickle Cell Patient
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Sickle cell disease SS or S-beta0 thalassemia
- Patient at steady state for at least 1 year, or currently at steady state without crisis, or during vaso-occlusive crisis or acute chest syndrome
- Age over 18 years old
You will not qualify if you...
- Patient objects to take part in the study
- Presence of hematologic disorders such as leukemia, myeloma, myelodysplastic syndrome, or myeloproliferative syndrome
- Immune thrombocytopenia or use of immunosuppressive or anti-inflammatory treatments including biotherapies, corticosteroids, or nonsteroidal anti-inflammatory drugs
- Use of anti-platelet agents
- Red blood cell exchange or transfusion within the past 3 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU de Toulouse
Toulouse, France, France, 31059
Actively Recruiting
Research Team
P
Pierre COUGOUL, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here